Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $5.3 million.

  • Lifecore Biomedical, Inc. \De\'s Cash from Operations fell 3865.31% to $5.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$206000.0, marking a year-over-year decrease of 18015.56%. This contributed to the annual value of -$206000.0 for FY2025, which is 18015.56% down from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s Cash from Operations stood at $5.3 million, which was down 3865.31% from $1.2 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Operations peaked at $8.7 million during Q2 2024, and registered a low of -$17.3 million during Q1 2022.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Cash from Operations averaged around -$2.4 million, with its median value being -$1.6 million (2022).
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Cash from Operations tumbled by 65649.41% in 2023, and later soared by 48532.27% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Cash from Operations stood at -$4.8 million in 2021, then soared by 51.08% to -$2.4 million in 2022, then soared by 154.74% to $1.3 million in 2023, then crashed by 576.71% to -$6.1 million in 2024, then skyrocketed by 187.08% to $5.3 million in 2025.
  • Its Cash from Operations stands at $5.3 million for Q2 2025, versus $1.2 million for Q1 2025 and -$6.1 million for Q4 2024.